| 1 |
29191521 | The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome. | 2018 Mar 1 |
1 |
| 2 |
27251582 | Effect of 3,4-diaminopyridine at the murine neuromuscular junction. | 2017 Feb |
1 |
| 3 |
28243504 | Aminopyridines for the treatment of neurologic disorders. | 2017 Feb |
1 |
| 4 |
26998103 | Successful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report. | 2016 Mar |
1 |
| 5 |
26152130 | Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers. | 2015 Aug |
2 |
| 6 |
21822385 | Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. | 2011 |
1 |
| 7 |
20058019 | 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. | 2010 Jun |
1 |
| 8 |
20483656 | Anharmonic vibrational analysis of 3,4-diaminopyridine and 3-aminopyridine by density functional theory calculations. | 2010 Sep 1 |
1 |
| 9 |
18718350 | Aminopyridines for the treatment of cerebellar and ocular motor disorders. | 2008 |
1 |
| 10 |
16472864 | Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. | 2006 Jul |
1 |
| 11 |
16537815 | Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome. | 2006 Apr |
1 |
| 12 |
16769957 | No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study. | 2006 Jun 13 |
1 |
| 13 |
15826992 | Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus. | 2005 Apr |
1 |
| 14 |
15184612 | Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. | 2004 Jun 8 |
1 |
| 15 |
12874393 | Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. | 2003 Jul 22 |
1 |
| 16 |
12176246 | Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods. | 2002 Aug 21 |
1 |
| 17 |
7527460 | Origin of delayed outward ionic current in charge movement traces from frog skeletal muscle. | 1994 Aug 15 |
1 |
| 18 |
20301347 | Congenital Myasthenic Syndromes Overview | 1993 |
1 |
| 19 |
1783919 | 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. | 1991 Dec |
1 |
| 20 |
1966500 | 3,4-Diaminopyridine induced stimulus-bound repetitive firing in frog sympathetic ganglion: no changes in postsynaptic membrane excitability. | 1990 |
1 |
| 21 |
2847755 | Changes in cytosolic free calcium with 1,2,3,4-tetrahydro-5-aminoacridine, 4-aminopyridine and 3,4-diaminopyridine. | 1988 Nov 1 |
1 |
| 22 |
2899012 | The actions of phenol and pentachlorophenol (PCP) on axonal conduction, ganglionic synaptic transmission, and the effect of pH changes. | 1988 |
1 |
| 23 |
3019820 | The effects of hemicholinium-3 (Hc-3) during tetanic (TP) and posttetanic potentiation (PTP) on sympathetic ganglion. | 1986 |
1 |
| 24 |
6308475 | Long-term regenerated nerve fibres retain sensitivity to potassium channel blocking agents. | 1983 Aug 18-24 |
1 |
| 25 |
6286925 | 3,4-diaminopyridine alters acetylcholine metabolism and behavior during hypoxia. | 1982 Sep |
1 |